



BAFNA PHARMACEUTICALS LIMITED

REGD. OFFICE: "BAFNA TOWERS" 299, THAMBU CHETTY STREET, CHENNAI-600 001, INDIA.
PHONE: 044-25267517/25270992/42677555, FAX: 91-44-25231264, Email: info@bafnapharma.com, Website: www.bafnapharma.com
CIN : L24294 TN1995PLC030698

Date: 28TH July 2022

Listing Department BSE Limited P J Towers Dalal Street, Mumbai – 400 001	Listing Department National Stock Exchange of India Limited Exchange Plaza, Bandra Kurla Complex, Bandra (E), Mumbai – 400051
Security code : 532989 Security ID : BAFNAPHARM	Symbol : BAFNAPH Series : EQ

Dear Sir,

Sub.:- Proceedings of 27th Annual General Meeting held on 28th JULY 2022

Ref.:- Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015

Please be informed that the 27th AGM of the Company was held on Thursday 28TH JULY 2022 through Video Conferencing ("VC")/ Other Audio Visual Means ("OAVM") at 11.00 a.m. IST.

In this regard please find attached the summary of the proceedings of the AGM of the Company.

The voting results of the 27th Annual General Meeting of the Company along with the Scrutinizer report will be shared shortly.

The 27th Annual General Meeting of the Company concluded at 11.30 A M

We request you to take the above information on your record

Thanking you.

For BAFNA PHARMACEUTICALS LIMITED


Roopa Ravikumar
Company Secretary



BAFNA PHARMACEUTICALS LIMITED

REGD. OFFICE: "BAFNA TOWERS" 299, THAMBU CHETTY STREET, CHENNAI-600 001, INDIA.
PHONE: 044-25267517/25270992/42677555, FAX: 91-44-25231264, Email: info@bafnapharma.com, Website: www.bafnapharma.com
CIN : L24294 TN1995PLC030698

Sub: Proceedings of 27th Annual General Meeting of the Company

In Compliance with Regulation 30 and other applicable provisions of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby submit the proceedings of 27th Annual General Meeting ('AGM') of the members of Bafna Pharmaceuticals Limited ('the Company'), held today i.e. THURSDAY, JULY 28, 2022 at 11:00 A.M IST through Video Conferencing (VC) / Other Audio Visual Means (OAVM) and the meeting concluded at 11:30 A M.

Chairperson of the Company Ms. S. Hemalatha welcomed the Shareholders, who were participating in the Meeting through Video Conferencing (VC) / Other Audio Visual Means (OAVM) and she has also briefed them about certain important points regarding video conferencing.

In compliance with the provisions of Section 108 of the Companies Act, 2013 read with Rule 20 of the Companies (Management and Administration) Rules, 2014, as amended and Regulation 44 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 and applicable provisions of the Companies Act, 2013 read with circulars, issued by Ministry of Corporate Affairs dated May 5, 2020, April 13, 2020, April 8, 2020 and SEBI Circular dated May 12, 2020, the Company has provided the facility to members, to exercise their right to vote, by electronic means on resolutions proposed to be passed at the AGM, either through Remote E-voting or E-voting during AGM.

The remote e-voting facility was provided by the Company from Monday, July 25th, 2022 at 09:00 AM IST to Wednesday, July 27th, 2022 at 5:00 PM IST to all the members of the Company, who were holding shares (either in physical form or dematerialized form) as on the cut-off date i.e. Thursday 21st July 2022.

The members of the Company were informed that "members attending the AGM, through Video Conferencing (VC) / Other Audio Visual Means (OAVM), who have not cast their votes by remote e-voting, can cast their vote through e-voting during the AGM.



BAFNA PHARMACEUTICALS LIMITED

REGD. OFFICE: "BAFNA TOWERS" 299, THAMBU CHETTY STREET, CHENNAI-600 001, INDIA.
PHONE: 044-25267517/25270992/42677555, FAX: 91-44-25231264, Email: info@bafnapharma.com, Website: www.bafnapharma.com
CIN : L24294 TN1995PLC030698

All efforts feasible under the circumstances have indeed been made by the Company to enable members to participate and vote on the item being considered in the meeting, after duly complying with the mechanism provided in MCA circular dtd May 5, 2020, April 13, 2020 & April 8, 2020 along with other provisions of the Act and Rules.

Ms. S. Hemalatha, Chairperson of the Board, chaired the meeting through Video Conferencing (VC) / Other Audio Visual Means (OAVM). All the Directors, Authorised Representatives of Statutory & Secretarial Auditors and Chief Financial Officer of the Company had also joined the meeting and welcomed & introduced all the dignitaries with the shareholders.

Since the quorum of the meeting was present, the Chairperson called the meeting to order and conducted the proceedings of the meeting through Video Conferencing (VC) / Other Audio Visual Means (OAVM).

she has further informed that M/s R. Sathyanaryanan & Co, Statutory Auditors of the Company and M/s. Balu Sridhar, Partner of M/s. A.K.Jain & Associates, Secretarial Auditors of the Company, have given the Audit Reports with observations or comments on financial transactions or matters, which do not have any adverse effect on the functioning of the Company, with the permission of members, the Auditors Reports as well as Directors Report of the Company, have been taken as read.

As the Meeting was convened through Video Conferencing (VC) / Other Audio Visual Means (OAVM), so, the following Resolutions had already been put to vote through remote e-voting thus the requirement to propose and second was not applicable:

S No.	Particulars of resolutions	Type of Resolution
ORDINARY BUSINESS		
1	Adoption of financial statement for the year ending 31 st March 2022	Ordinary Resolution
2	To appoint Mrs.Akila Chintalapati Raju (DIN:07590312)as Director liable to retire by rotation and being eligible offers herself for re appointment	Ordinary Resolution
3	To appoint M/s BRAHMAYYA & Co, Chartered Accountants as statutory auditors of the company and to fix their remuneration	Ordinary Resolution



BAFNA PHARMACEUTICALS LTD.,

REGD. OFFICE: "BAFNA TOWERS" 299, THAMBU CHETTY STREET, CHENNAI-600 001, INDIA.
PHONE: 044-25267517/25270992/42677555, FAX: 91-44-25231264, email: info@bafnapharma.com, Website, www.bafnapharma.com
CIN : L24294 TN1995PLC030698

Special business		
1	To ratify the remuneration of Cost Auditor, Mr. Sivashankaran & CO , Cost Accountants(FRN 100662)	Special resolution

The members were further informed that Mr Pankaj Mehta, Partner of A.K.Jain & Associates, Company Secretary in Practice, was appointed as Scrutinizer for the purpose of scrutinizing the e-voting process in a fair and transparent manner. Ms. S. Hemalatha, Chairperson of the meeting, authorized Mrs. Roopa Ravikumar , Company Secretary to receive the Scrutinizers' Report/Registers who shall countersign the same.

The Company Secretary further informed the members that the results of e-voting shall be disseminated to the Stock Exchanges at www.bseindia.com & www.nseindia.com and will also be displayed on the website of CDSL i.e www.evotingindia.com, the e-voting agency, on the Company's website at www.bafnapharma.com.

Ms. S. Hemalatha, Chairperson gave her speech to the shareholders.

Mrs. Roopa Ravikumar, Company Secretary of the Company, further informed that the members were given an opportunity to send their queries and questions, in advance at cs@bafnapharma.com.

Thereafter, the Company Secretary informed, that the members, who had not cast their vote already through Remote e-voting, may cast their vote by going to the e-voting platform and the same has been kept open till 11.30 A.M.

The chair person concluded the meeting with vote of thanks.

This is for your information and records please.

For Bafna Pharmaceuticals Limited


Roopa Ravikumar
Company Secretary